187 Phospholamban R14del Cardiomyopathy: a systematic summary of the pathophysiological mechanisms 7 209. Ponikowski, P. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37, (2016). 210. Abbasi, M., Negarandeh, R., Norouzadeh, R. & Mogadam, A. R. S. The Challenges of Living With an Implantable Cardioverter Defibrillator: A Qualitative Study. Iran. Red Crescent Med. J. 18, (2016). 211. van der Zwaag, P. A. et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14, 1199–1207 (2012). 212. Bleijendaal, H. et al. Computer versus cardiologist: Is a machine learning algorithm able to outperform an expert in diagnosing a phospholamban p.Arg14del mutation on the electrocardiogram? Heart Rhythm 18, 79–87 (2021). 213. Felix, S. E. A. et al. The role of long-term mechanical circulatory support in patients with advanced heart failure. Neth. Heart J. 28, 115–121 (2020). 214. van der Zwaag, P. A. et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14, 1199–1207 (2012). 215. Liu, B. et al. Conditional Up-Regulation of SERCA2a Exacerbates RyR2-Dependent Ventricular and Atrial Arrhythmias. Int. J. Mol. Sci. 21, (2020). 216. Kamel, S. M. et al. Istaroxime treatment ameliorates calcium dysregulation in a zebrafish model of phospholamban R14del cardiomyopathy. Nat. Commun. 12, 7151 (2021). 217. Badone, B. et al. Characterization of the PLN p.Arg14del Mutation in Human Induced Pluripotent Stem CellDerived Cardiomyocytes. Int. J. Mol. Sci. 22, (2021). 218. Junho, C. V. C., Caio-Silva, W., Trentin-Sonoda, M. & Carneiro-Ramos, M. S. An Overview of the Role of Calcium/ Calmodulin-Dependent Protein Kinase in Cardiorenal Syndrome. Front. Physiol. 0, (2020). 219. Haghighi, K. et al. Impaired Right Ventricular Calcium Cycling Is an Early Risk Factor in R14del-Phospholamban Arrhythmias. J Pers Med 11, (2021). 220. Cuello, F. et al. Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation. EMBO Mol. Med. 13, e13074 (2021). 221. Cuello, F. et al. Impairment of the ER/mitochondria compartment in human cardiomyocytes with PLN p.Arg14del mutation. EMBO Mol. Med. 13, e13074 (2021). 222. Eijgenraam, T. R. et al. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci. Rep. 10, 9819 (2020). 223. Eijgenraam, T. R. et al. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy. Sci. Rep. 10, 9819 (2020). 224. Te Rijdt, W. P. et al. Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST). Neth. Heart J. (2021) doi:10.1007/s12471-021-01584-5. 225. Feyen, D. A. M. et al. Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy. Circulation (2021) doi:10.1161/CIRCULATIONAHA.120.049844. 226. Stillitano, F. et al. Genomic correction of familial cardiomyopathy in human engineered cardiac tissues. Eur. Heart J. 37, 3282–3284 (2016). 227. Karakikes, I. et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat. Commun. 6, 6955 (2015). 228. Stroik, D. R. et al. Viral expression of a SERCA2a-activating PLB mutant improves calcium cycling and synchronicity in dilated cardiomyopathic hiPSC-CMs. J. Mol. Cell. Cardiol. 138, 59–65 (2020). 229. Karakikes, I. et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat. Commun. 6, 6955 (2015). 230. Haghighi, K. et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111, 869–876 (2003).
RkJQdWJsaXNoZXIy MTk4NDMw